Evidence map›Paper›PMID 40091073›Full record

ArticleDiscover oncology2025

Pan-cancer analysis and experimental verification of cytochrome B561 as a prognostic and therapeutic biomarker in breast cancer.

Xiaoting Qiu, Peizhang Liu, Hongxiang Lin, Zeyi Peng, Xinhao Sun, Guanting Dong, Yuanyuan Han, Zhijian Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoting Qiu *Department of Breast Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Peizhang Liu *School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350108, China.
Hongxiang LinSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350108, China.
Zeyi PengMassachusetts College Of Pharmacy And Health Sciences, Boston, MA, 02115, USA.
Xinhao SunCollege of Science, Northeastern University, Boston, MA, 02115, USA.
Guanting DongSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350108, China.
Yuanyuan HanInstitute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650000, China. hanyuan@imbcams.pumc.edu.cn.
Zhijian HuangDepartment of Breast Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China. ehuang27@fjmu.edu.cn.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-Gilead2024-PT-0047Science and Technology Talents and Platform Program for the Cultivation of Talents in Technological Innovation 202305AD160008
6 · The paper itself

Abstract

objectiveThis study investigates Cytochrome B561 (CYB561) expression in Pan-Cancer, its relationship with immune invasion, and its prognostic value in Breast Cancer (BRCA) patients.

methodsData from The Cancer Genome Atlas (TCGA) were analyzed. CYB561 expression in normal and tumor tissues was examined, with correlations to immune invasion, mutation, and immune checkpoints. Wilcoxon rank-sum test assessed expression differences. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted. Logistic regression, Kaplan-Meier, and Cox regression analyses evaluated clinicopathological features and survival outcomes. A Cox multivariate analysis-based Nomogram predicted CYB561's prognostic impact. CYB561 knockout in breast cancer cells assessed functional effects. Single-cell RNA sequencing identified prognostic biomarkers.

resultsCYB561 was highly expressed in most tumors. BRCA showed the highest correlation with ESTIMATE scores and significant negative correlation with immune checkpoints. High CYB561 expression correlated with specific clinicopathological features and survival outcomes. The nomogram predicted BRCA prognosis. CYB561 knockout inhibited breast cancer cell proliferation. Seven predictive agents for CYB561 inhibition were identified.

conclusionsCYB561 exhibits aberrant expression in tumors, particularly in BRCA, and serves as a predictive marker for immune-related therapies and a prognostic indicator in BRCA.

Indexed as

BiomarkerBreast cancerCYB561Immune invasionPan-cancerPrognosis

Identifiers

PMID40091073
PMCPMC11911281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.